SEC Comment Letter for Arcadia Biosciences, (RKDA) — Feb 5, 2026
Arcadia Biosciences, Inc.
Date: Feb. 5, 2026 · CIK: 0001469443 · Accession: 0000000000-26-001260
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-292993
Letter
Re: Arcadia Biosciences, Inc. Registration Statement on Form S-3 Filed January 28, 2026 File No. 333-292993 Dear Thomas Schaefer:
February 5, 2026
Thomas Schaefer Chief Executive Officer Arcadia Biosciences, Inc. 5956 Sherry Lane, Suite 2000 Dallas, TX 75225
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Liz Packebusch at 202-551-8749 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Energy &
Transportation
cc: C. Kevin Kelso, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> February 5, 2026 Thomas Schaefer Chief Executive Officer Arcadia Biosciences, Inc. 5956 Sherry Lane, Suite 2000 Dallas, TX 75225 Re: Arcadia Biosciences, Inc. Registration Statement on Form S-3 Filed January 28, 2026 File No. 333-292993 Dear Thomas Schaefer: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Liz Packebusch at 202-551-8749 with any questions. Sincerely, Division of Corporation Finance Office of Energy & Transportation cc: C. Kevin Kelso, Esq. </TEXT> </DOCUMENT>